The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.
iTeos Therapeutics, a US-based immuno-oncology drug spinout of Université catholique de Louvain (UCL) and Ludwig Institute for Cancer Research, filed for a $100m initial public offering on Wednesday.
Founded in 2011, iTeos is working on cancer immunotherapies and plans to channel the IPO proceeds into the clinical development of a small molecule drug candidate called EOS-850 and an antibody-based candidate dubbed EOS-448.
UCL’s Vives Louvain Technology Fund joined Ludwig Institute for Cancer Research, Hunza Ventures and Life…
